Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

GENz-trials: Revolutionizing Clinical Trials to Optimize Assessment of Healthcare Innovations

Project description

Reimagining how clinical trials are run

Clinical trials are essential for advancing medicine, but they are also expensive and time consuming. Delays related to trials block new treatments from reaching patients quickly. Finding the right participants is difficult, and traditional placebo groups can limit how many people get to try a new drug. The EU-funded GENz-trials project aims to modernise this process. Specifically, it uses data science to handle administrative tasks and match patients to trials using health records. By creating ‘digital twins’ and synthetic data to act as comparison groups, they can reduce the need for placebos. This makes research faster, more ethical, and fairer, helping new medicines get approved and into the hands of patients sooner.

Objective

GENz-trials, a private-public funded pan-European consortium, proposes a next-generation clinical trial framework that integrates data science, automation, and simulation technologies to transform how trials are designed, conducted, and evaluated. The strategy builds on three interlinked innovation pillars. i) Automation of critical trial workflows using generative AI for personalized informed consent, protocol drafting, monitoring, and regulatory submission, thereby reducing administrative burden and expediting trial initiation. ii) Artificial Intelligence (AI)-driven patient recruitment by analysing large-scale Electronic Health Records (EHRs), and real-world datasets to optimize matching between patients and trial protocols, improving enrolment rates, inclusiveness, and avoidance of patient dropout. iii) integration of Digital Twins (DTs) and Synthetic Control Arms (SCAs) for protocol optimization through in-silico simulation and enabling ethically sound alternatives to placebo groups, using real-world data to construct robust comparators with fewer enrolled participants. GENz-trials will serve as a platform for boosting innovation in the assessment of the added value of integrated healthcare solutions, providing a flexible and data-rich environment to evaluate not only pharmaceuticals, but also diagnostics, digital health tools, and therapeutic combinations, ultimately strengthening health technology assessment, regulatory decision-making, and reimbursement strategies. The GENz-trials framework will be unfolded in three phases: development of core tools; retrospective emulation of historical trials; and prospective validation through a Phase IV clinical equivalence trial comparing a generic anticoagulant with its branded counterpart. Through this phased strategy, GENz-trials aims to establish a more ethical, inclusive, and cost-effective paradigm for clinical research, accelerating the evaluation and deployment of life-saving healthcare innovations.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-IHI-2025-09-single-stage

See all projects funded under this call

Coordinator

ARISTOTELIO PANEPISTIMIO THESSALONIKIS
Net EU contribution
€ 565 000,00
Address
KEDEA BUILDING, TRITIS SEPTEMVRIOU, ARISTOTLE UNIVERSITY CAMPUS
546 36 THESSALONIKI
Greece
Region
Βόρεια Ελλάδα Κεντρική Μακεδονία Θεσσαλονίκη
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 565 000,00

Participants (15)